API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
XW004 (ecnoglutide) is a long-acting, cAMP signaling biased, glucagon-like peptide-1 (GLP-1) analog. It is under phase 1 clinical development for the treatment of type 2 diabetes and obesity.
Lead Product(s): Ecnoglutide
Therapeutic Area: Endocrinology Product Name: XW004
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2024
Details:
XW003 (ecnoglutide) is a novel, cAMP signaling biased, long-acting GLP-1 analogue optimized for improved biological activity. It is under phase 3 clinical development for the treatment of Adult Patients with Type 2 Diabetes.
Lead Product(s): Ecnoglutide
Therapeutic Area: Endocrinology Product Name: XW003
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2024
Details:
XW003 (ecnoglutide) is a novel, biased long-acting GLP-1 peptide analogue optimized for improved biological activity. GLP-1 analogs are effective therapies in managing type 2 diabetes, obesity, and have demonstrated clinical potential as a treatment for NASH.
Lead Product(s): Ecnoglutide
Therapeutic Area: Endocrinology Product Name: XW003
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2023
Details:
After 14 weeks of treatment, participants receiving 1.8 mg and 2.4 mg XW003 (ecnoglutide) achieved statistically significant mean body weight loss of 8.32 kg (9.6%) and 7.27 kg (9.0%), respectively, compared to 0.62 kg (0.9%) for those receiving placebo (P<0.0001).
Lead Product(s): Ecnoglutide
Therapeutic Area: Endocrinology Product Name: XW003
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2022
Details:
At week 20, participants receiving 0.4 mg, 0.8 mg, and 1.2 mg XW003 (ecnoglutide) had statistically significant HbA1c reductions from baseline of 1.8%, 1.9% and 2.4%, respectively, compared to 0.5% in participants receiving placebo (P < 0.0001).
Lead Product(s): Ecnoglutide
Therapeutic Area: Endocrinology Product Name: XW003
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 02, 2022
Details:
XW004 is an oral tablet formulation of Ecnoglutide, a novel long-lasting GLP-1 peptide analogue under development for the treatment of obesity, type 2 diabetes and NASH.
Lead Product(s): Ecnoglutide
Therapeutic Area: Nutrition and Weight Loss Product Name: XW004
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2022